智明達(688636.SH):擬對銘科思微增資1.78億元
格隆匯9月24日丨智明達(688636.SH)公佈,公司於2021年9月24日與李明、李智、銘科思微簽署《投資協議》,以自有現金方式出資1.78億元對銘科思微增資,取得3230萬元註冊資本(對應銘科思微增資後34.99%股權)。
通過本次投資,智明達將持有銘科思微34.99%股權,通過股權紐帶建立雙方的合作基礎,基於雙方更開放、充分的技術交流,有助於保障上市公司供應鏈的自主可控,同時,促進公司以嵌入式計算機為基礎,不斷跟進新的平台、技術,加快國產化的步伐,不斷優化產品性能和解決方案,提高公司可為下游客户提供定製化服務的競爭優勢,保持在軍用嵌入式計算機領域的優勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.